Search Results for 'Nsclc-Advanced'

Nsclc-Advanced published presentations and documents on DocSlides.

NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti

NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti

by sawyer742

Intervista a Federico . Cappuzzo. Background:. Pr...

SW GLH services for NSCLC – An update

SW GLH services for NSCLC – An update

by everly

Professor Rachel Butler. The genomic complexity of...

Consensus or Controversy?

Consensus or Controversy?

by okelly

Addressing Practical Clinical Questions Across the...

Multidisciplinary approach to lung cancer

Multidisciplinary approach to lung cancer

by elena

Kamil Konopka. Department of Oncology, University ...

NSCLC: Epidemiology and disease characteristics

NSCLC: Epidemiology and disease characteristics

by scarlett

NSCLC, non-small cell lung cancer.. Lung cancer in...

Please note, these are the actual video-recorded

Please note, these are the actual video-recorded

by chaptoe

proceedings from the live CME event and may includ...

Please note, these are the

Please note, these are the

by disclaimercanon

actual. . video-recorded proceedings from the . l...

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature

by stefany-barnette

The Cancer genome atlas (TCGA) and the search for...

The Role of Antiangiogenic Agents

The Role of Antiangiogenic Agents

by luanne-stotts

The Role of Antiangiogenic Agents in the Changin...

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

by pasty-toler

This program will include a discussion of off-lab...

by jane-oiler

of the expression of . 17-beta-hydroxysteroid . ...

by pasty-toler

MD. The Evolving Treatment Landscape in NSCLC: Co...

NSCLC with high PD-L1 expression on tumor cells or tumor-in

NSCLC with high PD-L1 expression on tumor cells or tumor-in

by test

Intervista a Federico . Cappuzzo. Background:. P...

Using Non-targeted Therapies in Targeted Lung Cancer Popula

Using Non-targeted Therapies in Targeted Lung Cancer Popula

by ellena-manuel

Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...

by luanne-stotts

Brada. . Torino. . 6 March 2015. Perspectives...

MEK Inhibitors and their potential role in relapsed NSCLC

MEK Inhibitors and their potential role in relapsed NSCLC

by debby-jeon

Ranee Mehra, MD. Fox Chase Cancer Center. Philade...

by cheryl-pisano

Le Chevalier, . MD. The Role of Translational Res...

by lorenzo155

4/1/24. Michael Forte, MD. Outline . Lung Cancer ...

INTRODUCTION RESULTS

INTRODUCTION RESULTS

by arjun383

Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...

Phase II studies of Nivolumab

Phase II studies of Nivolumab

by brianna

in patients with Advanced . Squamous. (SQ) or Non...

The formula Blueprint Medicines (BPMC)

The formula Blueprint Medicines (BPMC)

by erica

The sum of Blueprint’s pieces exceeds current va...

Striving for Consensus on the

Striving for Consensus on the

by samantha

Optimal Management of Metastatic . Non-Small Cell ...

Roberto Bianco Laboratori di Terapia Molecolare dei Tumori

Roberto Bianco Laboratori di Terapia Molecolare dei Tumori

by finley

Università . di Napoli “Federico II”. Innovat...

Second line treatments in WT

Second line treatments in WT

by deena

pts. : . which. . opportunities. with . biologic...

Istituto Toscano Tumori –Livorno, Italy

Istituto Toscano Tumori –Livorno, Italy

by payton

Federico . Cappuzzo. Istituto Toscano Tumori. Ospe...

New developments in oncological treatment for Stage 3 NSCLC

New developments in oncological treatment for Stage 3 NSCLC

by summer

Lung SSG 22. nd. May 2018. Gareth Ayre. Rationale...

CLINICAL EXPERIENCE OF NSCLC in RSDM

CLINICAL EXPERIENCE OF NSCLC in RSDM

by sophia

Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab ...

FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY

FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY

by pamela

Case study 9. Provided by . Dr Qamar Ghafoor, Clin...

Updates in the systemic treatment for lung

Updates in the systemic treatment for lung

by madeline

cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....

Checkpoint inhibitors for

Checkpoint inhibitors for

by paisley

NSCLC. An update. Solange Peters, MD-PhD. Oncology...

The Winship Cancer Institute of Emory University

The Winship Cancer Institute of Emory University

by jalin

July 22, 2023. Adjuvant immunotherapy for resectab...

ALK in lung cancer: Past, present, and future

ALK in lung cancer: Past, present, and future

by belinda

Gene Mutations in Lung . Adenocarcinomas. 17 years...

AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie

AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie

by susan2

DisclosureStatement:Theauthorhasnothingtodisclose....

NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM

NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM

by cecilia

NCCNCATEGORIESOFEVIDENCEANDCONSENSUSCategory1:Base...

cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi

cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi

by adia

RecommendationLoE, GoRScreening with LDCT (low-dos...

Jchem applications in Medchem

Jchem applications in Medchem

by StarsAndStripes

Prediction. . and. . Data Sorting. Zhengtao. Li...

ALL, Acute lymphoblastic leukemia;

ALL, Acute lymphoblastic leukemia;

by HappyHippo

BCMA, B-cell maturation antigen; DLBCL, diffuse la...

mRNA anticancer Vaccines

mRNA anticancer Vaccines

by byrne

breakthrough. . approach. in . cancer. . treatm...

Mechanisms of ALK Resistance & Implications for Treatment

Mechanisms of ALK Resistance & Implications for Treatment

by evans

Robert C. Doebele, MD, PhD. Associate Professor, ....

Targeting KRAS G12C in Solid Tumors

Targeting KRAS G12C in Solid Tumors

by morton

: . A . New Anticancer Approach . Marwan Fakih, ...